News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
68,373 Results
Type
Article (4505)
Company Profile (10)
Press Release (63854)
Multimedia
Podcasts (5)
Webinars (3)
Section
Business (21460)
Career Advice (123)
Deals (2332)
Drug Delivery (10)
Drug Development (7130)
Employer Resources (3)
FDA (1271)
Job Trends (1152)
News (30084)
Policy (2110)
Tag
2027 BioCapital Standard (2)
2027 BioMidwest Digital (1)
2027 BioMidwest Standard (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Standard (1)
2027 Genetown Standard (1)
2027 Pharm Country Digital (1)
2027 Pharm Country Standard (2)
40 Under 40 (1)
Academia (512)
Academic (1)
Accelerated approval (12)
ADA (1)
Allergies (15)
Alliances (6748)
ALS (26)
Alzheimer's disease (279)
Antibody-drug conjugate (ADC) (112)
Approvals (1349)
Artificial intelligence (193)
ASCO (76)
Autoimmune disease (43)
Automation (16)
Bankruptcy (18)
Belgium (4)
Best Places to Work (972)
BIO (5)
Biologics (6)
BIOSECURE Act (1)
Biosimilars (7)
BioSpace Insights (8)
Biotechnology (7)
Bispecific (8)
Bladder cancer (33)
Brain cancer (24)
Breast cancer (181)
Cancer (1478)
Cardiovascular disease (34)
Career advice (111)
Career pathing (4)
CAR-T (29)
CDC (2)
CDMO (6)
Cell therapy (70)
Cervical cancer (5)
Clinical research (5690)
Collaboration (447)
Commercialization (3)
Company closure (1)
Compensation (49)
Complete response letters (4)
COVID-19 (392)
CRISPR (28)
CRO (1)
C-suite (178)
Cystic fibrosis (21)
Data (1459)
Denatured (1)
Depression (9)
Dermatology (15)
Diabetes (29)
Diagnostics (3062)
Digital health (5)
Diversity (2)
Drug discovery (106)
Drug pricing (2)
Drug shortages (1)
Duchenne muscular dystrophy (24)
Earnings (5394)
Editorial (1)
Employer branding (1)
Employer resources (2)
ESMO (57)
Events (9598)
Executive appointments (140)
FDA (1665)
Fibrodysplasia Ossificans Progressiva (1)
Fragile X (1)
Friedreich's ataxia (4)
Frontotemporal dementia (5)
Funding (238)
Gene editing (46)
Generative AI (17)
Gene therapy (76)
GLP-1 (67)
Government (420)
Guidances (39)
Healthcare (1694)
Hematology (32)
HIV (5)
Huntington's disease (6)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (9)
Immunology and inflammation (26)
Immuno-oncology (17)
Indications (32)
Infectious disease (457)
Inflammatory bowel disease (33)
Influenza (28)
Intellectual property (31)
Interviews (11)
IPO (925)
IRA (1)
Job creations (204)
Job search strategy (100)
JPM (3)
Kidney cancer (4)
Kidney disease (10)
Labor market (2)
Layoffs (20)
Leadership (2)
Legal (248)
Licensing (9)
Liver cancer (12)
Longevity (11)
Lung cancer (233)
Lung diease (1)
Lymphoma (87)
Machine learning (16)
Management (1)
Manufacturing (77)
Marketing (3)
MASH (14)
Medical device (514)
Medtech (527)
Mergers & acquisitions (1509)
Metabolic disorders (81)
mRNA (26)
Multiple sclerosis (11)
Multispecific (2)
Netherlands (3)
Neurodegenerative disease (72)
Neuropsychiatric disorders (5)
Neuroscience (457)
NextGen: Class of 2026 (396)
Non-profit (419)
Now hiring (11)
Obesity (38)
Opinion (26)
Ovarian cancer (27)
Pain (23)
Pancreatic cancer (76)
Parkinson's disease (36)
Partnered (4)
Patents (54)
Patient recruitment (79)
Patient selection (6)
Peanut (5)
People (7591)
Peptides (1)
Pharmaceutical (1)
Phase 1 (2381)
Phase 2 (2601)
Phase 3 (1557)
Pipeline (1484)
Policy (8)
Postmarket research (107)
Preclinical (1767)
Press Release (18)
Prostate cancer (77)
Psychedelics (4)
Radioligand (2)
Radiopharmaceuticals (88)
Rare diseases (100)
Real estate (459)
Recruiting (1)
Regenerative medicine (3)
Regulatory (1987)
Reports (9)
Research institute (639)
Resumes & cover letters (15)
Rett syndrome (6)
RNA editing (6)
RSV (5)
Schizophrenia (9)
Series A (36)
Series B (18)
Sickle cell disease (5)
Spinal muscular atrophy (22)
Sponsored (7)
Startups (463)
Stem cells (1)
Stomach cancer (2)
Supply chain (4)
Switzerland (1)
Tariffs (1)
The Weekly (4)
Vaccines (56)
Venture capital (5)
Weight loss (16)
Women's health (14)
Worklife (1)
Date
Today (11)
Last 7 days (70)
Last 30 days (329)
Last 365 days (3169)
2026 (2684)
2025 (3018)
2024 (3415)
2023 (4195)
2022 (5473)
2021 (5636)
2020 (5211)
2019 (3593)
2018 (2705)
2017 (3405)
2016 (3406)
2015 (3996)
2014 (2756)
2013 (2314)
2012 (2478)
2011 (2649)
2010 (2205)
Location
Africa (66)
Alabama (4)
Alaska (1)
Arizona (24)
Asia (3658)
Australia (766)
California (1670)
Canada (334)
China (265)
Colorado (51)
Connecticut (75)
Delaware (72)
Europe (10416)
Florida (168)
Georgia (11)
Idaho (3)
Illinois (157)
India (13)
Indiana (75)
Iowa (3)
Japan (96)
Kansas (6)
Kentucky (3)
Louisiana (3)
Maine (3)
Maryland (155)
Massachusetts (1180)
Michigan (25)
Minnesota (67)
Missouri (22)
Montana (2)
Nebraska (1)
Nevada (5)
New Hampshire (2)
New Jersey (277)
New Mexico (8)
New York (489)
North Carolina (126)
North Dakota (5)
Northern California (914)
Ohio (46)
Oklahoma (1)
Oregon (4)
Pennsylvania (223)
Puerto Rico (1)
Rhode Island (12)
South America (77)
South Carolina (2)
Southern California (592)
Tennessee (34)
Texas (463)
United States (5631)
Utah (195)
Virginia (23)
Washington D.C. (6)
Washington State (148)
Wisconsin (48)
Wyoming (1)
68,373 Results for "diasorin molecular".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cerenome Launches CNSide® CSF Molecular Profile Tests
October 6, 2026
·
7 min read
Press Releases
New Innovative Molecular Technology Combination “LAMP + CRISPR” as CE-IVD
October 20, 2026
·
2 min read
Drug Development
5 molecular glues that could stick—and the companies stuck in
Molecular glue degraders are gaining traction in the clinic as well as funding from Big Pharma, with their potential to treat previously “undruggable” cancers and immunological diseases. Here are five clinical programs worth keeping an eye on.
July 6, 2026
·
6 min read
·
Michael Gibney
Press Releases
Hologic and Inpeco Announce Co-Marketing Partnership to Advance Molecular Laboratory Automation
October 20, 2026
·
4 min read
Deals
Novartis tightens bond with Orionis in up to $1.4B molecular glue deal
It’s the latest Big Pharma deal for molecular glue technology and Novartis’ second with Orionis Biosciences, after first linking up in March 2020. The backloaded agreement will see Novartis pay $40 million upfront.
June 11, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Invivoscribe® Advances Molecular Clonality Testing Portfolio with Comprehensive LymphoTrack® Flex Suite
October 6, 2026
·
3 min read
Press Releases
Scipher Medicine Launches PrismTcell™, the Next Molecular Treatment Response Signature, for Abatacept in Rheumatoid Arthritis
October 28, 2026
·
5 min read
Funding
Degron adds $40M to series A, supporting immunology plans for molecular glue platform
Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa Therapeutics last year to develop molecular glues for undisclosed immune-mediated conditions.
May 14, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
September 24, 2026
·
7 min read
Press Releases
Atlas Molecular Pharma Announces First Three Patients with Congenital Erythropoietic Porphyria Dosed with ATL-001
October 20, 2026
·
1 min read
1 of 6,838
Next
